Alimera Sciences Participating in Credit Suisse London One-on-One Healthcare Conference

ATLANTA, Feb. 20, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers , president and chief executive officer, will participate in the Credit Suisse London One-on-One Healthcare Conference on March 5 – 6, 2013 in London, UK.

About Alimera Sciences, Inc.

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently Alimera is focused on diseases affecting the back of the eye, or retina. Its primary product, ILUVIEN, is an intravitreal implant containing fluocinolone acetonide (FAc), a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease.

ICR, LLC 
for Alimera Sciences  
John Mills
310-954-1105
John.Mills@icrinc.com

 

SOURCE Alimera Sciences, Inc.

RELATED LINKS
http://www.alimerasciences.com